Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 958 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 958 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $46.24, for a total value of $44,297.92. Following the completion of the transaction, the insider now directly owns 6,887 shares in the company, valued at $318,454.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Friday, September 27th, Ventures Xi L.P. Avalon sold 49,231 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.45, for a total transaction of $2,286,779.95.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The stock was sold at an average price of $47.00, for a total transaction of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total transaction of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Trading Down 1.8 %

Shares of JANX traded down $0.82 during trading hours on Monday, hitting $45.43. The company had a trading volume of 879,722 shares, compared to its average volume of 722,238. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60. The company has a market capitalization of $2.36 billion, a PE ratio of -37.24 and a beta of 3.57. The company’s fifty day moving average price is $43.92 and its two-hundred day moving average price is $44.59.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.20. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The business had revenue of $8.90 million for the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics’s quarterly revenue was up 709.1% compared to the same quarter last year. Analysts forecast that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on JANX shares. Wedbush reissued an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research note on Monday, August 19th. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. Scotiabank reduced their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price objective on shares of Janux Therapeutics in a research note on Monday, September 16th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.13.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Swiss National Bank boosted its stake in Janux Therapeutics by 39.5% in the 4th quarter. Swiss National Bank now owns 31,800 shares of the company’s stock worth $341,000 after purchasing an additional 9,000 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth $553,000. China Universal Asset Management Co. Ltd. increased its position in shares of Janux Therapeutics by 82.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after acquiring an additional 4,400 shares during the period. Capstone Investment Advisors LLC acquired a new stake in Janux Therapeutics during the 1st quarter worth about $1,969,000. Finally, Lester Murray Antman dba SimplyRich purchased a new stake in Janux Therapeutics during the 1st quarter valued at about $300,000. 75.39% of the stock is owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.